Ann: Phosphagenics Pain Program Update , page-72

I hear you neg- before this thread I thought oxy was the priority and was to go through a relatively quick phase 2/3, establishing POH and forcing big pharma to notice and think of the possibilities (cheque book in hand.)

Woodpipe, you can't blame others for your lack of research. It has been clear since two AGMs ago that they were aiming for a 2015 release of Oxy pain patch. A bit of a shock for me at the time but they seem to be on target at this stage for that sort of timeframe. And it's been a few months now since the company indicated they were weighing up whether to go with a Phase 2/3 combined trial or spearate trials for OxyC. It's only since then that we've found out about the OxyM potential and now the further potential in chronic pain scenarios. All that is positive news but yes the market no longer reacts to the potential, the $110mill marketcap already encompasses the potential.

Other than some amazing revenue figures flowing from Elixia, ENA and other new revenue producing additions, I can't see a major price rise until it becomes clearer that a pain portfolio deal is nearing reality.